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Abstract 
 
Objectives: The Getting Out of Bed Scale (GOB) was validated as a health-related quality of life 
(HRQoL) variable in older women with early stage breast cancer, suggesting its potential as a concise 
yet powerful measure of motivation. The aim of our project was to assess the association between 
GOB and mortality over 10 years of follow-up.  
 
Materials and Methods: We studied 660 women ≥ 65-years old diagnosed with stage I-IIIA primary 
breast cancer. Data were collected over 10 years of follow-up from interviews, medical records, and 
death indexes.  
 
Results: Compared to women with lower GOB scores, women with higher GOB had an unadjusted 
hazard ratio (HR) of all-cause mortality of 0.78 at 5 years, 95% confidence interval (CI) (0.52, 1.19) 
and 0.77 at 10 years, 95%CI (0.59, 1.00). These associations diminished after adjusting for age and 
stage of breast cancer, and further after adjusting for other HRQoL variables including physical 
function, mental health, emotional health, psychosocial function, and social support. Unadjusted HRs 
of breast cancer-specific mortality were 0.92, 95%CI (0.49, 1.74), at 5 years, and 0.82, 95%CI (0.52, 
1.32), at 10 years. These associations also decreased in adjusted models. 
 
Conclusion: Women with higher GOB scores had a lower hazard of all-cause mortality in unadjusted 
analysis. This effect diminished after adjusting for confounding clinical and HRQoL variables. GOB is 
a measure of motivation that may not be independently associated with cancer mortality, but reflects 
other HRQoL variables making it a potential outcome to monitor in older cancer patients.  
 
 3 
Introduction 1 
 2 
The number of cancer survivors is expected to grow to 19 million by January 2024, contributed by 3 
advances in detection and treatment as well as an aging population (1). About 40% of new breast 4 
cancer diagnoses occur in those ≥65 years old, and these patients comprise the majority of breast 5 
cancer deaths and current breast cancer survivors (2). Among the challenges of caring for older 6 
patients with cancer is appropriately balancing treatment outcomes, such as survival, with health-7 
related quality of life (HRQoL) (3). There is growing evidence that HRQoL in cancer patients of all 8 
ages is not only an important outcome in itself but also a predictor of mortality (4-7).  9 
 10 
Motivation plays an important role in an older patient’s ability to overcome illness and stay engaged 11 
with healthy behaviors. Clough-Gorr et al. developed and validated a measure of motivation called 12 
the “Getting-Out-of-Bed (GOB) Scale” in a large cohort of older patients with early stage breast 13 
cancer (8). GOB was shown to correlate with several other HRQoL measures such as mental health 14 
and physical functioning, however GOB predicted certain outcomes and behaviors, such as 15 
participating in regular exercise, that were not predicted by HRQoL. Their results suggested that GOB 16 
reflects aspects of motivation potentially relevant to health behaviors and outcomes that overlap 17 
conceptually with, but are not entirely captured by, HRQoL. Measures similar to motivation, such as 18 
optimism and hope, have been linked to both disease-specific and all-cause mortality (9-11). 19 
However, GOB's ability to predict mortality, either independently or in association with HRQoL, has 20 
yet to be studied.  21 
 22 
In this secondary analysis of the same cohort of older women with early stage breast cancer studied 23 
by Clough-Gorr et al., we assessed the association between GOB and 5- and 10-year mortality, both 24 
all-cause and breast cancer-specific (BC-specific). We hypothesized that higher GOB scores would 25 
be associated with lower all-cause and BC-specific mortality. Moreover, we hypothesized that GOB 26 
would independently predict mortality, and included potential confounding clinical and HRQoL 27 
variables in our analysis to test this hypothesis. Figure 1 summarizes these hypothesized 28 
relationships: HRQoL measures have a direct effect on mortality and are associated with GOB. 29 
Knowledge of HRQoL will therefore allow an investigation into whether GOB has an independent 30 
effect on mortality (12). 31 
 32 
 33 
Materials and Methods 34 
 35 
Study Population 36 
 37 
The longitudinal study design and subject recruitment procedures have been reported previously (13). 38 
In brief, 660 women ≥65-years old with stage I tumor diameter ≥1cm or stage II-IIIA disease and 39 
permission from attending physicians to be contacted in four geographic regions (Los Angeles, 40 
California; Minnesota; North Carolina; Rhode Island) were identified through regular pathology report 41 
review at hospitals or collaborating tumor registries. Women could not have a prior primary breast 42 
cancer or simultaneously diagnosed or treated second primary tumor. Data were collected by medical 43 
record review (definitive surgery date, surgery type, tumor characteristics) and telephone interviews 44 
(socio-demographic, HRQoL variables, breast cancer therapy) beginning at least three-months after 45 
surgery and continuing annually for 10 years. Causes of death – characterized as breast cancer-46 
specific, all-cause, all-cancer-related – were collected through 10 years of follow-up. 47 
 48 
Mortality, all-cause and breast cancer-specific 49 
 50 
Decedents were identified by first and last name, middle initial, Social Security number, date of birth 51 
 4 
(DOB), sex, race, marital status, and state of residence matched against National Death Index (NDI) 52 
and Social Security Death Index (SSDI) records (14). Survival status at the end of 2007 was complete 53 
for all women.  54 
  55 
Socio-demographic characteristics 56 
We classified patient age as 65–69, 70–79, ≥80-years; race as white, other; education as <12-years, 57 
12-years, >12-years; and marital status as married (yes/no). 58 
 59 
Breast cancer characteristics 60 
 61 
We categorized stage as I-III using the TNM classification (15). Definitive primary therapy was 62 
mastectomy plus axillary lymph node dissection (ALND) or breast-conserving surgery (BCS) plus 63 
ALND.  64 
 65 
Getting out of Bed 66 
 67 
GOB (Table 1) consists of four items scored on an ordinal scale of 1 to 5. The language used in 68 
these items was intended to be straightforward using concepts and terms universally understood at a 69 
layperson’s level of understanding. GOB total score is calculated as an equally weighted sum of items 70 
(1=poor, 2=fair, 3=good, 4=very good, 5=excellent) giving a total score range from 4 to 20. The final 71 
score is transformed to 0-100, with a higher score indicating greater motivation (8).  72 
 73 
Health-related quality of life characteristics 74 
 75 
To further evaluate an independent association between GOB and mortality, we studied other HRQoL 76 
measures as potentially confounding variables in adjusted analyses, including physical function, 77 
general mental health, emotional health, psychosocial function, and social support. Physical function 78 
has been linked to mortality in older patients with cancer (7, 16). Moreover, physical function has 79 
been shown to be associated with other measures similar to motivation (8, 17-19). We calculated 80 
physical function using the 10-item Physical Function Index (PFI-10) from the Medical Outcomes 81 
Study Short Form-36 (MOS SF-36) (20). PFI-10 specifically has previously been linked to mortality in 82 
men and women (21, 22). Mental health has also been linked to survival in both older and younger 83 
cancer patients (23, 24). Furthermore, mental health has been shown to be associated with GOB and 84 
other measures similar to motivation (8, 25-27). General mental health was assessed by the Mental 85 
Health Index (MHI-5), a five-item measure of mental health from the MOS-SF-36 (20). MHI-5 86 
specifically has been linked to mortality in cancer patients and in other populations (14, 28, 29).  87 
 88 
Emotional health, psychosocial function, and social support have all been associated with measures 89 
similar to motivation (8, 30, 31). Breast cancer-specific emotional health (BCSEH) was assessed 90 
using a four-item measure reflecting how well the respondent was dealing with breast cancer-specific 91 
worries (32). We used the Psychosocial Summary Scale of the 17-item Cancer Rehabilitation 92 
Evaluation System-Short Form (CARES-SF) to capture cancer-specific psychosocial function (33). 93 
The CARES-SF item scores range from 1 to 4 (a higher score indicating more problems). Social 94 
support is related to survival in patients with breast and other cancers (34, 35). Social support was 95 
measured using a reduced set of eight items derived from the 19-item MOS Social Support Scale 96 
(mMOS-SS) (36).  97 
 98 
All of the above HRQoL measures were transformed to a 0-100 score, with higher scores indicating 99 
better physical function, mental health, emotional health, social support, and psychosocial function, 100 
respectively. 101 
 102 
 5 
Statistical methods 103 
 104 
The study population was described by counts, percentage (%), mean, standard deviation (SD), 105 
median, and interquartile range (IQR). We used Spearman’s rank correlation coefficient as an 106 
estimate of correlation. Mortality rates were calculated by the number of events divided by the total 107 
person-years under observation. We used Multiple Imputation (MI) to address missing baseline data, 108 
using a fully conditional specification approach (37). We assumed missing data to be missing at 109 
random (MAR) (38). In addition to variables used in the main analysis model, including GOB, age, 110 
stage of breast cancer, PFI-10, MHI-5, BCSEH, CARES-SF, and mMOS-SS, we used enrollment site, 111 
education, number of comorbidities, body mass index, type of therapy, tamoxifen prescribed, 112 
recurrence of breast cancer, and received chemotherapy in the imputation model to make the MAR 113 
assumption more plausible (39). Further, we included survival status and the Nelson-Aalen estimator 114 
in the imputation model to account for survival (38). We imputed continuous variables by predictive 115 
mean matching and categorical variables by polytomous logistic regression. We generated 25 116 
multiple imputed datasets. All reported results are based on MI. As a sensitivity analysis we report 117 
complete case results. The associations between GOB and survival time were evaluated by modeling 118 
the hazard of dying using Cox regression models from all-cause mortality and BC-specific mortality. 119 
We did the same to assess the association between GOB and all-cancer mortality. We report hazard 120 
ratios (HR) as effect measures. Observation time began at the date of definitive surgery and ended 121 
on the date of death, 31 December 2002 (5-year survival) or 31 December 2007 (10-year survival), 122 
whichever came first. The proportional hazard assumption was tested by Schoenfeld’s test (40). We 123 
present unadjusted models (i.e., Model 1: only GOB as predictor), and models adjusted for 1) age, 124 
stage of breast cancer (Model 2), and then additionally for 2) PFI-10, MHI-5, BCSEH, CARES-SF and 125 
mMOS-SS (Model 3). GOB and HRQoL measures were a priori dichotomized at a cutoff point of ≥ 80 126 
versus < 80 (14, 41). A cutoff of 80 was chosen since it was similar to the other cutoffs used and 127 
nearly equally divided the population in half. To account for the possibility that GOB might be 128 
associated with mortality but with a different cutoff, we performed a sensitivity analysis using GOB 129 
and the HRQoL measures as continuous linear predictors, i.e. on their original 0-100 scale, in 130 
modeling. 131 
 132 
Approval of the study was obtained from each institutional review board associated with the four 133 
geographic regions from which the study participants were identified and consented. 134 
 135 
Results  136 
 137 
Study population 138 
 139 
Socio-demographic, breast cancer, and HRQoL characteristics of the baseline study population are 140 
shown in Table 2. The majority of women were ≥ 70 years (74.0%), white (93.9%), and had at least 141 
12 years of education (82.4%). Approximately half had stage I disease and the majority (82%) 142 
received either a mastectomy, or BCS followed by radiation.  Nearly half (47.7%) of the population 143 
had GOB ≥ 80, 64.8% had PFI-10 ≥ 80, and 68.9% had MHI-5 ≥ 80. 61.1% had BCSEH ≥ 80, 57.7% 144 
had CARES-SF ≥ 80, and 50.5% had mMOS-SS ≥ 80. The percentage of missing values of baseline 145 
characteristics ranged from 0.1% (missing BC stage) to 6.8% (missing BCSEH) with 3.6% of GOB 146 
baseline values missing.  147 
 148 
GOB and mortality 149 
 150 
Through 31 December 2002 (five years of follow-up), 99 (15.0%) women died, and of these, 39 151 
(39.4%) were due to breast cancer, with 2712 persons-years of observation. The 5-year all-cause 152 
mortality rate was 3.6%, 95%CI (3.0% - 4.4%), and the 5-year BC-specific mortality rate was 1.4%, 153 
 6 
95%CI (1.1% - 2.0%). Through 31 December 2007 (10 years of follow-up), 230 (34.8%) women died, 154 
and of these, 72 (31.3%) were due to breast cancer, with 5179 persons-years of observation. The 10-155 
year all-cause mortality rate was 4.4%, 95%CI (3.9% - 5.1%), and the 10-year BC-specific mortality 156 
rate was 1.4% 95%CI (1.1% - 1.8%).  157 
 158 
Table 3 displays the results of unadjusted (Model 1) and adjusted regression models (Model 2: 159 
adjusted for age and stage of BC, and Model 3: adjusted for age, stage of BC, and HRQoL 160 
measures) at both at 5- and 10-year time points. At 5 years, women with GOB ≥ 80 had an 161 
unadjusted HR of all-cause mortality of 0.78, 95%CI (0.52, 1.19), compared to women with GOB < 162 
80. In adjusted models this hazard ratio increased to 0.87, 95%CI (0.57, 1.32), in Model 2, and to 163 
1.04, 95%CI (0.65, 1.66), in Model 3. At 10 years, women with GOB ≥ 80 had an unadjusted HR of 164 
all-cause mortality of 0.77, 95%CI (0.59, 1.00), compared to women with GOB < 80. This HR 165 
increased from Model 2 [HR 0.84, 95%CI (0.64, 1.10)] to Model 3 [HR 1.08, 95%CI (0.80, 1.46)]. 166 
Unadjusted HRs of BC-specific mortality were 0.92, 95%CI (0.49, 1.74), at 5 years, and 0.82, 95%CI 167 
(0.52, 1.32), at 10 years. These HRs also increased in adjusted models. There was no evidence of 168 
violation of the proportional hazard assumption across all covariates. Kaplan-Meier survival curves 169 
from complete case results are shown in Figure 2, showing trends toward improved all-cause and 170 
breast cancer-specific survival in patients with GOB ≥ 80. Table 4 shows the Spearman rank 171 
correlations among baseline HRQoL measures. Weak to moderate positive correlations were found 172 
between GOB and PFI-10, MHI-5, BCSEH, mMOS-SS, and CARES-SF. 173 
 174 
Supplemental Table 1 summarizes sensitivity results from a complete case analysis. Estimates are 175 
comparable to estimates from Table 3. Supplemental Table 2 reports MI Cox regression estimates 176 
using GOB and HRQoL measures as linear variables per one-unit standard deviation increase. The 177 
results are similar to results using dichotomized variables. Supplemental Table 3 shows results from 178 
adjusted and unadjusted regression models testing the association between GOB and all-cancer 179 
mortality. At 5 years, women with GOB ≥ 80 had an unadjusted HR of all-cancer mortality of 0.86, 180 
95%CI (0.50, 1.48) that increased towards 1 after adjusted analyses. Results were similar at 10 181 
years. 182 
 183 
Discussion 184 
 185 
In a cohort of older women with early stage breast cancer we determined whether a measure of 186 
motivation, the 4-item GOB scale, was associated with mortality over 10 years of follow-up. We found 187 
that women with better motivation had a lower hazard of all-cause mortality in unadjusted analysis. 188 
This effect diminished after adjusting for confounding variables age, stage of breast cancer, and other 189 
HRQoL measures. We found no association between motivation and BC-specific mortality at 5 years 190 
and 10 years. The similar hazard ratios found by our sensitivity analysis using GOB as a continuous 191 
variable suggest that selecting a different cutoff other than 80 would not have changed the results. 192 
Our findings extend the goals of the original GOB validation study, which highlighted the need to 193 
further test GOB’s predictive ability over longer periods of time (8). Our results partially support our 194 
hypothesis in that GOB would be related to mortality, however they do not support our hypothesis that 195 
this relationship is independent of the other clinical and HRQoL variables included as confounders in 196 
adjusted analyses (as depicted in Figure 1). 197 
 198 
Previous studies have measured concepts similar to motivation such as hope and optimism and 199 
found them to be related to health outcomes in a variety of patient populations. However the evidence 200 
is equivocal that these concepts are independently associated with mortality in cancer patients (42-201 
45). In support of an independent association, “dispositional optimism” was found to predict one-year 202 
survival in patients with head and neck cancer (46), “pessimism” was linked to lower survival in lung 203 
 7 
cancer patients (47), and a hope for the curability of cancer correlated with higher survival in 204 
nonmetastatic colon cancer patients (48). Other studies do not support an independent association 205 
between measures similar to motivation and mortality: in over 90,000 women from the Women’s 206 
Health Initiative who were at baseline free of cardiovascular disease and cancer, optimism measured 207 
using the Life Orientation Test-Revised was found to be independently associated with a lower 208 
hazard of coronary heart disease and coronary heart disease-related mortality in all patients, but was 209 
found only in black patients to be independently associated with cancer-related mortality (49). Our 210 
analysis of all-cancer mortality found a weak association with high GOB in unadjusted analyses that 211 
diminished after adjustment for age, stage, and other HRQoL variables, akin to the results of the 212 
analysis conducted on our main outcomes of breast cancer-specific and all-cause mortality 213 
(Supplementary Table 3). In patients with advanced colon cancer, Schofield et al. measured 214 
hopefulness and optimism using the State Hope Scale (50) and Life Orientation Test (51), 215 
respectively (24). The authors found that baseline hopefulness was associated with overall survival in 216 
unadjusted analysis, whereas optimism was not. Similar to our study, the association between 217 
hopefulness and survival weakened after adjusting for known prognostic variables. Our results 218 
suggest that much of the decrease in mortality in women with baseline GOB ≥ 80 vs. women with 219 
GOB < 80 was because women with GOB≥ 80 were younger and/or had less advanced disease, not 220 
because they had higher levels of motivation per se. Moreover, younger patients are more likely to 221 
have fewer comorbidities and receive guideline-recommended therapy – two factors not included in 222 
our analysis that might also contribute to lower mortality (52-57).  223 
 224 
Our study shows that the relation between GOB and mortality is confounded not only by age and 225 
cancer stage, but also by the HRQoL variables included in our study (Table 3). We found weak to 226 
moderate correlations among GOB, MHI-5, PFI-10, BCSEH, CARES-SF, and mMOS-SS (Table 4), 227 
complementing the original GOB study that found associations between GOB and MHI-5 as well as 228 
GOB and PFI-10 both at baseline and at 6 months (8). Other studies have found relations between 229 
measures similar to motivation (GOB) and each of the other HRQoL variables studied (8, 17-19, 25-230 
27, 30, 31). Physical function and mental health were not only related to GOB (Table 4) but were also 231 
independently associated with mortality (Table 3, PFI-10 with all-cause mortality and MHI-5 with both 232 
all-cause and BC-specific mortality). This finding reinforces prior research (16, 23, 52, 58). Schofield 233 
et al. noted that after adjusting for factors such as depression – a variable similar to general mental 234 
health that they found to be negatively correlated with hope – the unadjusted association between 235 
hope and mortality weakened (24). Likewise, our results suggest that even after adjusting for age and 236 
stage, much of the remaining decrease in mortality in women with baseline GOB ≥ 80 was because 237 
these women had higher scores of mental health and physical functioning, not a higher score of 238 
motivation.  239 
 240 
Strengths of our study include the long follow-up period, tracking mortality in participants for 10 years. 241 
Further, survival status was complete through 10 years, thus avoiding selection bias due to lost to 242 
follow-up. Limitations include a population that was largely white, well-educated, and from four 243 
specific regions in the US, limiting the generalizability of our findings. Whereas we found that GOB 244 
was not independently associated with breast cancer-specific or all-cause mortality, we did not test 245 
whether it was associated with other important outcomes such as disability-free life expectancy or 246 
hospitalization. If an independent association between motivation and mortality does exist, a larger 247 
sample size may have been necessary to detect it. Moreover, GOB was validated in only one study, 248 
and GOB’s four questions and the manner in which they are worded might not adequately stratify 249 
patients into high and low risk in terms of mortality; measures of motivation with more items and 250 
different content might be more discriminatory. Lastly, the low number of deaths within 5 years and 251 
breast cancer-related deaths within 10 years coupled with the observed moderate correlations 252 
between investigated HRQoL measures increase imprecision in model estimates, given by the bias-253 
 8 
variance trade-off. Thus, point estimates from adjusted models in our data might vary across different 254 
models due to wide confidence intervals rather than reflecting the true population values. 255 
 256 
In conclusion, our results suggest that a previously validated measure of motivation, GOB, is 257 
associated with other important HRQoL variables. However, independent of these variables and age 258 
and stage of cancer, GOB is weakly associated with mortality. There is a great need for efficient 259 
strategies to risk stratify older adults with cancer, as they are different from younger patients with 260 
respect to life expectancy, physiologic reserve, and life values (59). Our study suggests that GOB 261 
does not contribute to the goal of aiding providers and researchers with a stand-alone tool that can 262 
predict mortality in older cancer patients; other strategies, namely Comprehensive Geriatric 263 
Assessment, have shown more promise to that end (52, 60-67). However, GOB is a measure of 264 
motivation that reflects other HRQoL variables and like these other HRQoL variables might be an 265 
important outcome to monitor in older cancer patients, either by itself or as part of longer instruments. 266 
Its brevity paired with its proven internal reliability and stability over time support this purpose (8). It 267 
has not only been shown to correlate with other HRQoL variables, as in the current study, but has 268 
also been shown to be predictive of HRQoL variables such as mental, emotional, and self-perceived 269 
health. More promising are our findings that build on the growing evidence linking mental and 270 
physical function to mortality, both of which are domains of the Comprehensive Geriatric Assessment. 271 
Further research using these HRQoL variables by themselves or in combination with other known 272 
predictive factors such as age and stage could lead to brief yet powerful prognostic tools to help 273 
guide treatment of older cancer patients. 274 
 275 
 276 
 277 
 278 
 279 
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Figure 1: Hypothesized relationships among Getting Out of Bed (GOB), health-related quality of life 
(HRQoL) variables, and mortality*. 
 
 
 
* GOB affects mortality and is associated with HRQoL, which also affects mortality. Therefore, any 
observed effect GOB may have on mortality might in fact be due to its association with HRQoL (12). This 
confounding situation can be solved by adjusting for HRQoL, such that GOB is an independent predictor 
for mortality. 
HRQoL
MortalityGOB
Table 1: Getting out of bed questionnaire.  
"This set of questions asks about things that encourage you to get up each morning and begin your 
day. Please indicate whether it is an Excellent description of you, a Very Good description of you, a 
Good description of you, a Fair description of you, or a Poor description of you. 
GOB Item Excellent Very Good Good Fair Poor 
1. I am the type of person who almost always 
has a reason to get out of bed in the morning. 5 4 3 2 1 
2. It is important for me to get out of bed each 
day and to do what I have to do. 5 4 3 2 1 
3. I have reasons in my life to get up and to 
get going every day. 5 4 3 2 1 
4. In the future, I am sure there will be things 
in my life to keep me getting up each day. 5 4 3 2 1 
  
Table 2: Baseline socio-demographic and health-related characteristics in a population of older women 
with breast cancer (N=660). 
Characteristic n (%) / Median (IQR) 
Enrollment site 
 Los Angeles 150 (22.7) 
 Rhode Island 163 (24.7) 
 Minnesota 188 (28.5) 
 North Carolina 159 (24.1) 
Age 
 65–69 years 172 (26.1) 
 70–79 years 372 (56.4) 
 80+ years 116 (17.6) 
Ethnicity 
 White 620 (93.9) 
 Other 40 (6.1) 
Education 
 Less than 12 years 115 (17.4) 
 12 years 228 (34.5) 
 More than 12 years 316 (47.9) 
 Missing 1 (0.1) 
Marital status  
 Married 304 (46.1) 
 Not married 356 (53.9) 
Breast Cancer Stage 
 I 336 (50.9) 
 II 298 (45.1) 
 III 25 (3.8) 
 Missing 1 (0.1) 
Type of therapy  
    BCS 317 (48.0) 
    Mastectomy 316 (47.9) 
    Other 17 (2.6) 
 Missing 10 (1.5) 
GOB 75.0 (31.2) 
    GOB ≥ 80 315 (47.7) 
    GOB < 80 321 (48.6) 
 Missing 24 (3.6) 
PFI-10 90.0 (33.3) 
    PFI-10 ≥ 80 428 (64.8) 
    PFI-10 < 80 229 (34.7) 
 Missing 3 (0.5) 
MHI-5 84.0 (20.0) 
    MHI-5 ≥ 80 455 (68.9) 
    MHI-5 < 80 204 (30.9) 
 Missing 1 (0.5) 
BCSEH 75.0 (31.2) 
    BCSEH ≥ 80 403 (61.1) 
    BCSEH < 80 212 (32.1) 
 Missing 45 (6.8) 
CARES-SF 82.1 (19.6) 
    CARES-SF ≥ 80 381 (57.7) 
    CARES-SF < 80 279 (42.3) 
mMOS-SS 81.2 (31.2) 
    mMOS-SS ≥ 80 333 (50.5) 
    mMOS-SS < 80 327 (49.5) 
IQR: Interquartile range; GOB: Getting-Out-of-Bed Scale; PFI-10: Physical Function Index; MHI-5: 
General mental health; BCSEH: Breast cancer-specific emotional health; CARES-SF: Cancer-specific 
psychosocial function; mMOS-SS: Modified Social Support Scale. 
 
Table 3: Five- and ten-year survival analysis for all-cause and breast-cancer-specific mortality*. 
  All-cause mortality Breast-cancer-specific mortality 
  5-years 10-years 5-years 10-years 
    HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) 
Model 1†:     
GOB ≥ 80 at baseline 0.78 (0.52, 1.19) 0.77 (0.59, 1.00) 0.92 (0.49, 1.74) 0.82 (0.52, 1.32) 
Model 2†:     
GOB ≥ 80 at baseline 0.87 (0.57, 1.32) 0.84 (0.64, 1.10) 1.05 (0.55, 1.99) 0.89 (0.56, 1.43) 
Age 65-69 years  Reference Reference Reference Reference 
 70-79 years 1.05 (0.61, 1.83) 1.43 (1.00, 2.05) 1.11 (0.46, 2.70) 1.17 (0.65, 2.1) 
 80+ years 2.92 (1.65, 5.15) 3.18 (2.14, 4.71) 3.04 (1.23, 7.51) 2.00 (1.02, 3.95) 
Stage  I Reference Reference Reference Reference 
 II 1.51 (1.0, 2.30) 1.42 (1.09, 1.86) 6.84 (2.65, 17.7) 5.27 (2.81, 9.86) 
  III 3.05 (1.43, 6.54) 3.20 (1.91, 5.37) 12.2 (3.28, 45.6) 10.2 (4.01, 26.0) 
Model 3†:     
GOB ≥ 80 at baseline 1.04 (0.65, 1.66) 1.08 (0.80, 1.46) 1.10 (0.53, 2.27) 1.02 (0.59, 1.74) 
Age 65-69 years Reference Reference Reference Reference 
 70-79 years 1.02 (0.58, 1.77) 1.37 (0.96, 1.97) 1.10 (0.45, 2.67) 1.18 (0.65, 2.12) 
 80+ years 3.25 (1.79, 5.89) 3.11 (2.07, 4.66) 3.62 (1.4, 9.40) 2.27 (1.12, 4.61) 
Stage  I Reference Reference Reference Reference 
 II 1.42 (0.93, 2.15) 1.40 (1.06, 1.83) 6.44 (2.49, 16.7) 5.12 (2.73, 9.61) 
 III 2.58 (1.19, 5.62) 3.05 (1.80, 5.14) 10.2 (2.66, 38.8) 8.93 (3.45, 23.1) 
PFI-10 ≥ 80 at baseline 0.64 (0.43, 0.97) 0.63 (0.48, 0.82) 0.83 (0.43, 1.61) 0.85 (0.52, 1.39) 
MHI-5 ≥ 80 at baseline 0.43 (0.28, 0.68) 0.60 (0.45, 0.80) 0.46 (0.22, 0.97) 0.54 (0.32, 0.93) 
BCSEH ≥ 80 at baseline 1.21 (0.72, 2.04) 0.93 (0.66, 1.31) 1.46 (0.65, 3.26) 1.14 (0.63, 2.08) 
CARES-SF ≥ 80 at baseline 0.73 (0.47, 1.12) 0.96 (0.72, 1.26) 0.75 (0.38, 1.50) 0.88 (0.53, 1.46) 
mMOS-SS ≥ 80 at baseline 1.26 (0.81, 1.98) 0.84 (0.62, 1.12) 1.41 (0.68, 2.91) 1.06 (0.63, 1.78) 
HR: Hazard ratio; CI: Confidence interval; GOB: Getting-Out-of-Bed Scale; PFI-10: Physical Function 
Index; MHI-5: General mental health; BCSEH: Breast cancer-specific emotional health; CARES-SF: 
Cancer-specific psychosocial function; mMOS-SS: Modified Social Support Scale. 
* All estimates from multiple imputed baseline variables using Cox regression. 
† Model 1: Unadjusted; Model 2/3: Adjusted for all listed variables. 
Table 4: Spearman rank correlations between baseline HRQoL measures. 
  GOB PFI-10 MHI-5 BCSEH CARES-SF mMOS-SS 
GOB 1.00      
PFI-10 0.17 1.00     
MHI-5 0.33 0.26 1.00    
BCSEH  0.49 0.11 0.44 1.00   
CARES-SF 0.26 0.16 0.43 0.52 1.00  
mMOS-SS 0.36 0.14 0.31 0.45 0.39 1.00 
GOB: Getting-Out-of-Bed Scale; PFI-10: Physical Function Index; MHI-5: General mental health; BCSEH: 
Breast cancer-specific emotional health; CARES-SF: Cancer-specific psychosocial function; mMOS-SS: 
Modified Social Support Scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: Kaplan-Meier survival curves comparing A) survival from all-cause mortality and B) survival 
from breast-cancer-specific mortality between subjects with GOB ≥ 80 and those with GOB < 80*.  
 
* Graphs based on complete case results.  
Supplemental Table 1: Five- and ten-year survival analysis for all-cause and breast-cancer-specific 
mortality from complete case analysis using Cox regression models. 
  All-cause mortality Breast-cancer-specific mortality 
  5-years 10-years 5-years 10-years 
    HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) 
Model 1*:     
GOB ≥ 80 at baseline 0.80 (0.53, 1.21) 0.78 (0.60, 1.02) 0.94 (0.50, 1.77) 0.84 (0.52, 1.34) 
Model 2*:     
GOB ≥ 80 at baseline 0.86 (0.56, 1.3) 0.84 (0.64, 1.10) 0.99 (0.52, 1.91) 0.87 (0.54, 1.41) 
Age 65-69 years Reference Reference Reference Reference 
 70-79 years 0.98 (0.56, 1.72) 1.40 (0.98, 2.01) 1.15 (0.47, 2.78) 1.18 (0.65, 2.13) 
 80+ years 2.68 (1.50, 4.78) 3.05 (2.05, 4.54) 2.73 (1.08, 6.89) 1.88 (0.94, 3.78) 
Stage of breast 
cancer I Reference Reference Reference Reference 
 II 1.54 (1.00, 2.37) 1.47 (1.12, 1.94) 6.54 (2.52, 17.0) 5.61 (2.92, 10.8) 
  III 3.00 (1.33, 6.74) 3.12 (1.80, 5.39) 12.4 (3.33, 46.4) 11.4 (4.40, 29.4) 
Model 3*:     
GOB ≥ 80 at baseline 0.95 (0.59, 1.55) 1.05 (0.77, 1.42) 0.94 (0.44, 2.02) 0.93 (0.53, 1.63) 
Age 65-69 years Reference Reference Reference Reference 
 70-79 years 1.03 (0.58, 1.82) 1.37 (0.95, 1.97) 1.32 (0.51, 3.36) 1.26 (0.69, 2.32) 
 80+ years 2.73 (1.44, 5.17) 2.84 (1.86, 4.34) 3.28 (1.15, 9.40) 2.14 (1.00, 4.58) 
Stage of breast 
cancer I Reference Reference Reference Reference 
 II 1.38 (0.88, 2.17) 1.37 (1.03, 1.83) 5.52 (2.11, 14.5) 4.97 (2.57, 9.60) 
 III 2.36 (1.01, 5.49) 2.90 (1.65, 5.09) 9.23 (2.38, 35.8) 8.93 (3.37, 23.7) 
PFI-10 ≥ 80 at baseline 0.60 (0.39, 0.94) 0.63 (0.47, 0.84) 0.85 (0.42, 1.72) 0.95 (0.57, 1.60) 
MHI-5 ≥ 80 at baseline 0.45 (0.27, 0.74) 0.58 (0.43, 0.79) 0.51 (0.23, 1.13) 0.53 (0.30, 0.92) 
BCSEH ≥ 80 at baseline 1.43 (0.84, 2.43) 1.00 (0.70, 1.41) 1.65 (0.72, 3.78) 1.23 (0.67, 2.28) 
CARES-SF ≥ 80 at baseline 0.74 (0.46, 1.17) 1.01 (0.75, 1.36) 0.78 (0.37, 1.63) 0.97 (0.56, 1.66) 
mMOS-SS ≥ 80 at baseline 1.27 (0.78, 2.07) 0.83 (0.61, 1.14) 1.49 (0.69, 3.23) 1.12 (0.65, 1.94) 
HR: Hazard ratio; CI: Confidence interval; GOB: Getting-Out-of-Bed Scale; PFI-10: Physical Function 
Index; MHI-5: General mental health; BCSEH: Breast cancer-specific emotional health; CARES-SF: 
Cancer-specific psychosocial function; mMOS-SS: Modified Social Support Scale. 
* Model 1: Unadjusted; Model 2/3: Adjusted for all listed variables. 
 
  
Supplemental Table 2: Five- and ten-year survival analysis for all-cause and breast-cancer-specific 
mortality using non-dichotomized standardized health measures from Cox regression models. 
  All-cause mortality Breast-cancer-specific mortality 
  5-years 10-years 5-years 10-years 
    HR (95%CI) HR (95%CI) HR (95%CI) HR (95%CI) 
Model 1*:     
GOB linear† 0.90 (0.74, 1.09) 0.85 (0.75, 0.96) 1.00 (0.73, 1.36) 0.95 (0.75, 1.19) 
Model 2*:     
GOB linear† 0.96 (0.79, 1.17) 0.89 (0.79, 1.01) 1.09 (0.79, 1.50) 1.01 (0.80, 1.27) 
Age 65-69 years Reference Reference Reference Reference 
 70-79 years 1.06 (0.61, 1.84) 1.43 (1.00, 2.04) 1.13 (0.47, 2.73) 1.18 (0.66, 2.13) 
 80+ years 2.94 (1.66, 5.20) 3.13 (2.11, 4.64) 3.11 (1.26, 7.70) 2.04 (1.03, 4.02) 
Stage of breast 
cancer I Reference Reference Reference Reference 
 II 1.51 (1.00, 2.29) 1.41 (1.08, 1.85) 6.89 (2.67, 17.8) 5.28 (2.82, 9.88) 
  III 3.07 (1.43, 6.56) 3.20 (1.91, 5.36) 12.6 (3.28, 45.7) 10.3 (4.06, 26.3) 
Model 3*:     
GOB linear† 1.08 (0.86, 1.36) 1.06 (0.91, 1.23) 1.11 (0.77, 1.62) 1.12 (0.84, 1.48) 
Age 65-69 years Reference Reference Reference Reference 
 70-79 years 1.07 (0.61, 1.88) 1.40 (0.98, 2.01) 1.23 (0.50, 3.02) 1.27 (0.70, 2.30) 
 80+ years 3.06 (1.67, 5.61) 3.11 (2.06, 4.70) 3.68 (1.38, 9.84) 2.42 (1.17, 5.01) 
Stage of breast 
cancer I Reference Reference Reference Reference 
 II 1.44 (0.94, 2.19) 1.41 (1.07, 1.86) 6.34 (2.44, 16.5) 5.10 (2.71, 9.59) 
 III 2.82 (1.29, 6.16) 3.07 (1.81, 5.20) 11.2 (2.90, 43.1) 9.10 (3.49, 23.7) 
PFI-10 at baseline, linear† 0.80 (0.66, 0.97) 0.76 (0.67, 0.87) 1.03 (0.73, 1.45) 0.98 (0.76, 1.26) 
MHI-5 at baseline,  linear† 0.79 (0.63, 0.99) 0.84 (0.72, 0.97) 0.79 (0.55, 1.12) 0.77 (0.60, 0.99) 
BCSEH at baseline,  linear† 1.08 (0.82, 1.42) 0.96 (0.80, 1.14) 1.31 (0.85, 2.01) 1.03 (0.76, 1.41) 
CARES-SF at baseline,  linear† 0.95 (0.74, 1.22) 1.04 (0.88, 1.22) 0.79 (0.54, 1.15) 0.98 (0.74, 1.31) 
mMOS-SS at baseline,  linear† 1.04 (0.81, 1.33) 0.94 (0.80, 1.10) 1.09 (0.73, 1.63) 1.01 (0.75, 1.35) 
HR: Hazard ratio; CI: Confidence interval; GOB: Getting-Out-of-Bed Scale; PFI-10: Physical Function 
Index; MHI-5: General mental health; BCSEH: Breast cancer-specific emotional health; CARES-SF: 
Cancer-specific psychosocial function; mMOS-SS: Modified Social Support Scale. 
* Model 1: Unadjusted; Model 2/3: Adjusted for all listed variables. 
† Per 1-unit SD increase. 
 
 
 
Supplemental Table 3: Five- and ten-year survival analysis for all-cancer mortality*. 
  All-cancer mortality 
  5-years 10-years 
    HR (95%CI) HR (95%CI) 
Model 1†:   
GOB ≥ 80 at baseline 0.86 (0.50, 1.48) 0.78 (0.53, 1.14) 
Model 2†:   
GOB ≥ 80 at baseline 0.93 (0.53, 1.61) 0.83 (0.56, 1.22) 
Age 65-69 years Reference Reference 
 70-79 years 0.77 (0.39, 1.53) 1.14 (0.71, 1.82) 
 80+ years 2.18 (1.08, 4.42) 1.87 (1.08, 3.25) 
Stage  I Reference Reference 
 II 2.35 (1.31, 4.21) 2.60 (1.71, 3.96) 
  III 3.59 (1.21, 10.7) 5.64 (2.77, 11.5) 
Model 3†:   
GOB ≥ 80 at baseline 0.96 (0.51, 1.80) 0.92 (0.59, 1.42) 
Age 65-69 years Reference Reference 
 70-79 years 0.76 (0.38, 1.52) 1.13 (0.70, 1.81) 
 80+ years 2.59 (1.23, 5.44) 1.91 (1.08, 3.39) 
Stage  I Reference Reference 
 II 2.23 (1.25, 4.00) 2.56 (1.68, 3.90) 
 III 2.91 (0.96, 8.88) 5.18 (2.51, 10.7) 
PFI-10 ≥ 80 at baseline 0.89 (0.51, 1.55) 0.76 (0.51, 1.12) 
MHI-5 ≥ 80 at baseline 0.45 (0.24, 0.83) 0.72 (0.47, 1.11) 
BCSEH ≥ 80 at baseline 1.34 (0.68, 2.66) 1.05 (0.65, 1.70) 
CARES-SF ≥ 80 at 
baseline 0.85 (0.48, 1.52) 0.91 (0.60, 1.37) 
mMOS-SS ≥ 80 at baseline 1.44 (0.79, 2.63) 1.02 (0.68, 1.55) 
HR: Hazard ratio; CI: Confidence interval; GOB: Getting-Out-of-Bed Scale; PFI-10: Physical Function 
Index; MHI-5: General mental health; BCSEH: Breast cancer-specific emotional health; CARES-SF: 
Cancer-specific psychosocial function; mMOS-SS: Modified Social Support Scale. 
* All estimates from multiple imputed baseline variables using Cox regression. 
† Model 1: Unadjusted; Model 2/3: Adjusted for all listed variables. 
 
